Physician profile
Beth Eargle
NPI 1720096548
$1,721.13
in general payments reported to CMS, 2019-2025
20 companies · $622 in 2025
The $622 reported for 2025 was more than what 98% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $245 · 2023: $101 · 2024: $580 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $292.41 | 2021-2025 | Bridion, Dificid |
| Medtronic, INC. | $229.14 | 2021-2025 | Invos, Retia Medical, Mcgrath Mac |
| Aimmune Therapeutics, INC. | $174.17 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $106.76 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $89.39 | 2023-2025 | Entyvio, Eohilia |
| Acacia Pharma INC | $82.90 | 2022 | |
| Janssen Biotech, INC. | $66.24 | 2023-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $55.28 | 2025 | Ibsrela |
| Fisher & Paykel Healthcare INC | $50.19 | 2025 | Fisher & Paykel Healthcare |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.57 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Edwards Lifesciences Corporation | $30.85 | 2022 | |
| Haemonetics Corporation | $26.51 | 2025 | Teg5000 Hemostasis Analyzer |
| Chiesi USA, INC. | $22.45 | 2025 | Cleviprex |
| Becton, Dickinson and Company | $22.36 | 2025 | Hemosphere |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $17.05 | 2024 | Sucraid |
| Eagle Pharmaceuticals, INC. | $16.63 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.64 | 2021 | |
| Silk Road Medical, INC. | $14.86 | 2021 | |
| Madrigal Pharmaceuticals | $13.55 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Eargle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.